

Glabellar lines - Pipeline Insight, 2021

<https://marketpublishers.com/r/G2B9EF2C93B8EN.html>

Date: June 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: G2B9EF2C93B8EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Glabellar lines - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Glabellar lines pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Glabellar lines Understanding

Glabellar lines: Overview

Glabellar lines or glabella lines appear in the glabella, the skin over the forehead, between and above the eyebrows and right above the nose. When a person wrinkle his/her face by talking, yawning, laughing, or making expressions, the glabella is the skin most affected by the muscle activity beneath the surface. Over time, as a result of a combination of causes including genetics, skin tightness, muscle activity, face shape, and various intrinsic and extrinsic causes, the lines that appear in your glabella may remain permanently, evolving into wavy furrows in the forehead. These are known as glabellar lines and they can continuously worsen over time if not treated.

'Glabellar lines - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Glabellar lines pipeline landscape is provided which includes the disease overview and Glabellar lines treatment guidelines. The assessment part of the report embraces, in depth Glabellar lines commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glabellar lines collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Glabellar lines R&D. The therapies under development are focused on novel approaches to treat/improve Glabellar lines.

Glabellar lines Emerging Drugs Chapters

This segment of the Glabellar lines report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glabellar lines Emerging Drugs

ATGC-100: EuBiologics

ATGC-100 is botulinum toxin A just like Allergan's Botox. Eubiologics and ATGC are jointly developing ATGC-100. Botulinum Toxin is a toxin produced only by the gram-positive anaerobic bacteria, *Clostridium botulinum*, inducing temporary muscle paralysis by reversibly blocking the secretion of acetylcholine at a neuromuscular junction.

DaxibotulinumtoxinA for Injection (DAXI): Revance Therapeutics

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA and is currently under regulatory review. DAXI has been evaluated in three

Phase 3 trials (SAKURA 1, 2, 3), the largest aesthetic neuromodulator clinical program ever conducted for the treatment of glabellar (frown) lines. In the Phase 3 pivotal program, the median time to loss of none or mild wrinkle severity was 24 weeks and the median time to return to baseline wrinkle severity was approximately 28 weeks.

Further product details are provided in the report..

Glabellar lines: Therapeutic Assessment

This segment of the report provides insights about the different Glabellar lines drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Glabellar lines

There are approx. 4+ key companies which are developing the therapies for Glabellar lines. The companies which have their Glabellar lines drug candidates in the most advanced stage, i.e. preregistration include, Revance Therapeutics.

Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Glabellar lines pipeline report provides the therapeutic assessment of the pipeline drugs

by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Glabellar lines: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glabellar lines therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glabellar lines drugs.

Glabellar lines Report Insights

Glabellar lines Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Glabellar lines Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Glabellar lines drugs?

How many Glabellar lines drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glabellar lines?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glabellar lines therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Glabellar lines and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

ATGC Biotech

EuBiologics

Ipsen

Bonti

Eirion Therapeutics

Roche

Galderma

Key Products

ATGC-100

Daxibotulinumtoxin A

IPN-10200

EB-001

AI-09

RelabotulinumtoxinA

Contents

Introduction

Executive Summary

Glabellar lines: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Glabellar lines – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Glabellar lines companies' collaborations, Licensing, Acquisition -Deal Value Trends

Glabellar lines Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

DaxibotulinumtoxinA for Injection (DAXI): Revance Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

EB-001: Bonti

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I/II)

- Comparative Analysis

IPN-10200: Ipsen

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report..

Preclinical and Discovery Stage Products

- Comparative Analysis

AI-09: Eirion Therapeutics

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report..

Inactive Products

- Comparative Analysis

Glabellar lines Key Companies

Glabellar lines Key Products

Glabellar lines- Unmet Needs

Glabellar lines- Market Drivers and Barriers

Glabellar lines- Future Perspectives and Conclusion

Glabellar lines Analyst Views

Glabellar lines Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Glabellar lines
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Glabellar lines
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Glabellar lines - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/G2B9EF2C93B8EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2B9EF2C93B8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970